Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Malignant Melanoma

  Free Subscription


3 Ann Surg Oncol
1 BMC Cancer
2 Clin Cancer Res
2 Int J Cancer
1 J Invest Dermatol
2 J Surg Oncol
2 Lancet Oncol
7 Melanoma Res
1 Oncogene
1 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Ann Surg Oncol

  1. ZABOR EC, Coit D, Gershenwald JE, McMasters KM, et al
    Variability in Predictions from Online Tools: A Demonstration Using Internet-Based Melanoma Predictors.
    Ann Surg Oncol. 2018 Feb 22. pii: 10.1245/s10434-018-6370.
    PubMed     Text format     Abstract available

  2. BELLO DM, Ariyan CE
    Adjuvant Therapy in the Treatment of Melanoma.
    Ann Surg Oncol. 2018 Feb 21. pii: 10.1245/s10434-018-6376.
    PubMed     Text format    

  3. WRIGHT GP, Marsh JW, Varma MK, Doherty MG, et al
    Liver Resection After Selective Internal Radiation Therapy with Yttrium-90 is Safe and Feasible: A Bi-institutional Analysis.
    Ann Surg Oncol. 2017;24:906-913.
    PubMed     Text format     Abstract available

    BMC Cancer

  4. SOOTICHOTE R, Thuwajit P, Singsuksawat E, Warnnissorn M, et al
    Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8.
    BMC Cancer. 2018;18:231.
    PubMed     Text format     Abstract available

    Clin Cancer Res

  5. PARKHURST M, Gros A, Pasetto A, Prickett T, et al
    Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
    Clin Cancer Res. 2017;23:2491-2505.
    PubMed     Text format     Abstract available

  6. INFANTE JR, Hollebecque A, Postel-Vinay S, Bauer TM, et al
    Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors.
    Clin Cancer Res. 2017;23:2423-2432.
    PubMed     Text format     Abstract available

    Int J Cancer

    Immigration is the most likely reason for the generational change in melanoma incidence in Queensland, Australia.
    Int J Cancer. 2018 Feb 28. doi: 10.1002/ijc.31348.
    PubMed     Text format    

  8. LIYANAGE UE, Law MH, Ong JS, Cust AE, et al
    Polyunsaturated fatty acids and risk of melanoma: A Mendelian randomisation analysis.
    Int J Cancer. 2018 Feb 22. doi: 10.1002/ijc.31334.
    PubMed     Text format     Abstract available

    J Invest Dermatol

  9. SOLER-CARDONA A, Forsthuber A, Lipp K, Ebersberger S, et al
    CXCL5 facilitates melanoma cell-neutrophil interaction and lymph node metastasis.
    J Invest Dermatol. 2018 Feb 20. pii: S0022-202X(18)30125.
    PubMed     Text format     Abstract available

    J Surg Oncol

    Melanoma patterns of care in Ontario: A call for a strategic alignment of multidisciplinary care-Response to letter.
    J Surg Oncol. 2018 Feb 26. doi: 10.1002/jso.25006.
    PubMed     Text format    

  11. BRANDAO PHDM, Bertolli E, Doria-Filho E, Santos Filho IDAO, et al
    In transit sentinel node drainage as a prognostic factor for patients with cutaneous melanoma.
    J Surg Oncol. 2018 Feb 26. doi: 10.1002/jso.25023.
    PubMed     Text format     Abstract available

    Lancet Oncol

  12. MAIO M, Lewis K, Demidov L, Mandala M, et al
    Adjuvant vemurafenib in resected, BRAF(V600) mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
    Lancet Oncol. 2018 Feb 21. pii: S1470-2045(18)30106.
    PubMed     Text format     Abstract available

  13. WARNER AB, Postow MA
    The brim of uncertainty in adjuvant treatment of melanoma.
    Lancet Oncol. 2018 Feb 21. pii: S1470-2045(18)30150.
    PubMed     Text format    

    Melanoma Res

  14. BASSOLI S, Pellegrini C, Longo C, Di Nardo L, et al
    Clinical, dermoscopic, and confocal features of nevi and melanomas in a multiple primary melanoma patient with the MITF p.E318K homozygous mutation.
    Melanoma Res. 2018;28:166-169.
    PubMed     Text format    

  15. AMODE R, Baroudjian B, Kowal A, Jebali M, et al
    Anti-programmed cell death protein 1 tolerance and efficacy after ipilimumab immunotherapy: observational study of 39 patients.
    Melanoma Res. 2017;27:110-115.
    PubMed     Text format     Abstract available

  16. BLACKMON JT, Dhawan R, Terry NL, Conry RM, et al
    Response of BRAF inhibitor-associated squamous cell lung carcinoma to drug withdrawal.
    Melanoma Res. 2017;27:159-163.
    PubMed     Text format     Abstract available

  17. GONZALEZ-CAO M, Mayo de Las Casas C, Jordana Ariza N, Manzano JL, et al
    Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy.
    Melanoma Res. 2018 Feb 23. doi: 10.1097/CMR.0000000000000432.
    PubMed     Text format     Abstract available

  18. DIMITRIOU F, Frauchiger AL, Urosevic-Maiwald M, Naegeli MC, et al
    Sarcoid-like reactions in patients receiving modern melanoma treatment.
    Melanoma Res. 2018 Feb 26. doi: 10.1097/CMR.0000000000000437.
    PubMed     Text format     Abstract available

  19. MACHIRAJU D, Moll I, Gebhardt C, Sucker A, et al
    STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-alpha.
    Melanoma Res. 2018 Feb 26. doi: 10.1097/CMR.0000000000000435.
    PubMed     Text format     Abstract available

  20. TAKAHASHI A, Tsutsumida A, Namikawa K, Yamazaki N, et al
    Fulminant type 1 diabetes associated with nivolumab in a patient with metastatic melanoma.
    Melanoma Res. 2018;28:159-160.
    PubMed     Text format    


  21. TUSA I, Gagliardi S, Tubita A, Pandolfi S, et al
    ERK5 is activated by oncogenic BRAF and promotes melanoma growth.
    Oncogene. 2018 Feb 27. pii: 10.1038/s41388-018-0164.
    PubMed     Text format     Abstract available

    PLoS One

  22. JOSHI SS, Jiang S, Unni E, Goding SR, et al
    17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.
    PLoS One. 2018;13:e0191264.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.